F2 and blood coagulation disease: In this trial study, although rsTM was shown to be biologically active by reducing the plasma levels of the coagulation activation markers D-dimer, prothrombin fragment F1+2, and thrombin-antithrombin complexes, it did not significantly reduce the 28-day mortality rate in patients with sepsis-associated coagulopathy [56].